ArticleInternational immunopharmacology2017

Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo.

Melek M E Sunay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.